Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism

Although substantial progress has been made in the last 5 years in the development of vasodilator and inotropic drugs for the management of patients with severe chronic heart failure, much of the enthusiasm that surrounded the introduction of many of these agents has subsequently been tempered by reports of drug failure or adverse reactions. In this review and analysis, currently available vasodilator and inotropic agents are critically and comparatively evaluated to assess their respective advantages and limitations. It is apparent that the ability of most of these drugs to produce substantial clinical benefits in patients with severe heart failure has probably been overstated. Therapy fails to achieve the desired clinical results all too frequently, possibly as the result of: the choice of an ineffective drug; the administration of an effective drug in subtherapeutic doses; the administration of an effective drug to improperly selected patients; the failure of initial hemodynamic benefits to be sustained; the occurrence of severe or serious adverse reactions; and the failure to alter concomitant therapy appropriately. The present analysis indicates that there is no uniformly effective or safe vasodilator or inotropic drug for patients with severe heart failure; all agents have important limitations. Of the available therapeutic choices, however, long-term converting enzyme inhibition appears to produce more consistent hemodynamic and clinical benefits with an acceptable degree of adverse reactions than other pharmacologic approaches for the management of these severely ill patients.

This article has been cited by other articles:

				J. L. Fleg, P. C. Hinton, E. G. Lakatta, F. I. Marcus, T. W. Smith, H. C. Strauss, and M. A. Hlatky Physician Utilization of Laboratory Procedures to Monitor Outpatients With Congestive Heart Failure Arch Intern Med, February 1, 1989; 149(2): 393 - 396. [Abstract] [PDF]

				C. D. Mulrow, J. P. Mulrow, W. D. Linn, C. Aguilar, and G. Ramirez Relative Efficacy of Vasodilator Therapy in Chronic Congestive Heart Failure: Implications of Randomized Trials JAMA, June 17, 1988; 259(23): 3422 - 3426. [Abstract] [PDF]

				M. PACKER, W. H. LEE, N. MEDINA, M. YUSHAK, and P. D. KESSLER Functional Renal Insufficiency During Long-Term Therapy with Captopril and Enalapril in Severe Chronic Heart Failure Ann Intern Med, March 1, 1987; 106(3): 346 - 354. [Abstract] [PDF]

				M. PACKER, W. H. LEE, N. MEDINA, and M. YUSHAK Influence of Renal Function on the Hemodynamic and Clinical Responses to Long-Term Captopril Therapy in Severe Chronic Heart Failure Ann Intern Med, February 1, 1986; 104(2): 147 - 154. [Abstract] [PDF]

				J. Abrams Vasodilator Therapy for Chronic Congestive Heart Failure JAMA, December 6, 1985; 254(21): 3070 - 3074. [Abstract] [PDF]

				M. PACKER Vasodilator Therapy for Primary Pulmonary Hypertension: Limitations and Hazards Ann Intern Med, August 1, 1985; 103(2): 258 - 270. [Abstract] [PDF]